The US Food and Drug Administration confirmed that Optimer Pharmaceuticals’ new antibiotic drug, fidaxomicin, is effective in combating a bacterial infection

Share prices of Optimer saw an 11 percent rise to $13.20 before ending the session at $13.13.
Should the drug be given approval by the FDA, then this will be the first from Optimer to reach the US market and analysts predict that the drug would fetch over $200 million in annual sales.
Source-Medindia